Description
The National Institute of Allergy and Infectious Diseases (NIAID) intends to award a sole source contract to Emergent Product Development Gaithersburg Inc. for the maintenance of the Biologics Master File 018816, which contains information for the HIV-1 Adenovirus Type 4-Vectored (A549 cells) Vaccines, Live, Aqueous (Ad4-HIV). The contract will provide for the maintenance of the master file throughout the remaining 84, 96, 108, and 120-month stability timepoints. The period of performance will be from April 27, 2026 to March 31, 2027, with options for two additional years. The NAICS code for this acquisition is 541714, Research and Development in Biotechnology (Except Nanobiotechnology).
Key points:
• The contract is for the maintenance of the Biologics Master File 018816
• The period of performance will be from April 27, 2026 to March 31, 2027, with options for two additional years
• The NAICS code for this acquisition is 541714, Research and Development in Biotechnology (Except Nanobiotechnology)
• The contract will be awarded on a sole source basis to Emergent Product Development Gaithersburg Inc.
• The government plans to award a contract within 14 days of the notice
Attached files
Contact
Linda E Smith(Contracting Officer)